WuXi AppTec launches new service to deliver more shots on goal for drug discovery

WuXi AppTec Expands Site in the United States
WuXi AppTec opens a New Jersey-based site. (PRNewsfoto/WuXi AppTec)

Shanghai-based WuXi AppTec has launched its so-called DELight service aimed at making “cost-effective and efficient hit finding services” to speed up early drug discovery.

DELight, or DNA Encoded Library, is a self-serve product that gives researchers direct access to a collection of more than 8 billion compounds.

“Through the DELight service package, WuXi will provide a DNA Encoded Library kit and a user manual/protocols document to the research organization,” the CRO and drug discovery company explained in a statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: WuXi AppTec hires cancer drug development vet as new CMO

When a researcher gets hold of the kit, they make an affinity selection and then send it back to WuXi, which in turn will perform an analysis and send a summary report back to the researcher.

WuXi explains that when compared to traditional DNA-based drug discovery services, “DELight is a more convenient, efficient and economical service package, allowing researchers to perform their own affinity selection with minimum assay development and without disclosing target information.”

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.